Lifeboat Foundation

Today, we are pleased to announce a new collaborative video that we have been working on about life extension!

James Peyer has been a scientist, entrepreneur, and advisor to biotechs and pharma companies, always with a specialization for developing new classes of therapeutics. James founded Apollo to support biotech entrepreneurs strategically, scientifically, and financially as they create the next generation of medicines.

James Peyer received his PhD from the University of Texas Southwestern Medical Center in Dallas, where he was a National Science Foundation Fellow and worked on the basic biology of stem cells and improving gene therapies. He founded his first company, Genotyp, at 21 to overhaul hands-on science education in the US. Genotyp’s innovative biotech equipment leasing model and instructor training earned it the approval of the White House and the National Institutes of Health. It became the first biotech company to receive funding through Kickstarter.com. He received a BA with special honors from the University of Chicago, where he studied immunology.

Discoveries in aging biology are ready for acceleration to the clinic, where they can treat age-related disease and extend healthy lifespan.

Continue reading “Interview with Apollo Ventures which funds anti-aging companies” »

Today, we want to draw your attention to a new study that looks at the role of chronic age-related inflammation and the decline of nerve regeneration.

Inflammaging drives age-related loss of tissue regeneration

Inflammation can be beneficial and serves an important purpose: it spurs regeneration and immune responses while combating pathogens and other invaders. This kind of inflammation tends to be short-lived and localized to an area of injury. However, there is another form of inflammation, a chronic, smouldering kind that accompanies aging: this is often called inflammaging.

Water infrastructure in the western United States was funded in the early and mid-20th Century by federal financing through the Bureau of Reclamation, but such financing has declined in recent decades and there has been increased interest in alternative approaches to infrastructure funding. A new Journal of the American Water Resources Association article notes that two of these approaches—public-private partnerships and loan guarantees—are hampered by existing federal budgetary policies, however.

In the article, Dr. Martin Doyle, of Duke University, notes that significant policy changes are needed to allow private capital to play an important role in funding and financing water systems characterized by aging infrastructure.

“Everyone likes the idea of bringing more private capital to aging infrastructure; but no one is able, or willing, to get into the really weedy details of policy changes necessary to make such investments possible,” he said.

Today, we are delighted to announce that we have launched a new crowdfunding campaign on Lifespan.io: the NAD+ Mouse Project by Dr. David Sinclair and his team at Harvard Medical School.

The first long-term lifespan study in mice involving supplementation with NMN, a precursor of NAD+ metabolism, which has been shown to reduce aging markers and increase sirtuin activity. We propose to conduct a longevity study using NMN in the drinking water of wild-type mice. We also propose to test NMN on a novel model of accelerated aging mice known as ICE mice (Induced Changes In Epigenome).

Today, we are delighted to announce that we have launched a new crowdfunding campaign on Lifespan.io: the NAD+ Mouse Project by Dr. David Sinclair and his team at Harvard Medical School.

NAD+ is a vitally important molecule that is found in every cell in your body and is involved in DNA repair, tissue growth, nutrient sensing and metabolism, cell-to-cell signaling, and many other cellular processes. Quite simply, without NAD+, cells would not work and life would be impossible. If you would like to learn more about NAD+ and its role in aging, check out our articles here, here, and here.

On the new article by Prof Dr S. Olshansky published in JAMA, advising to focus on healthspan extension not on lifespan extension. No, I personally believe that we can still focus on lifespan extension. We could obtain indefinite healthy life extension by different methods of rejuvenation because the rejuvenation process eliminates the main reason for sickness ie the aging diseases and renders us healthy again! And also only through indefinite life extension we could close the gap of tens of years between the lifespan in different social and ethnic groups (Lens-Pechakova, Rejuvenation Res. 2014 Apr;17:239–42)

Clinicians, scientists and public health professionals should proudly “declare victory” in their efforts to extend the human lifespan to its very limits, according to University of Illinois at Chicago epidemiologist S. Jay Olshansky.

In an article published in the Journal of the American Medical Association, Olshansky writes that the focus should shift to compressing the “red zone” — the time at the end of life characterized by frailty and disease, and extending the “healthspan” — the length of time when a person is alive and healthy.

Continue reading “Shifting focus from life extension to ‘healthspan’ extension” »

A diet rich in fiber helps reduce inflammation in murine brains.

According to a new study performed by University of Illinois researchers and published in Frontiers in Immunology, a diet rich in fiber reduces inflammation in aged mice, both in the guts and the brain. This beneficial reduction is due to high levels of butyrate, which result from the fermentation of fiber during digestion [1].

Study abstract

Continue reading “High-Fiber Diet Reduces Brain Inflammation in Older Mice” »

Today, we have an update from the MitoSENS team over at the SENS Research Foundation. As some of you may recall, MitoSENS was the first project we hosted on our research fundraising platform Lifespan.io back in August 2015. The project was successfully funded and raised $46,128, which was 153% of the funds needed. The extra funds were used to increase the scope of the project, which resulted in a paper being published in the prestigious Oxford Journal.

Since then, the team has been busy working on transferring the other mitochondrial genes to the nucleus, and they have given us an update to let everyone know how things are progressing at the lab. Dr. Matthew “Oki” O’Connor had the following to say about progress and the future.

Continue reading “MitoSENS Update September 2018” »